株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

骨髄線維症治療薬の世界市場:2018年~2022年

Global Myelofibrosis Therapeutics Market 2018-2022

発行 TechNavio (Infiniti Research Ltd.) 商品コード 773824
出版日 ページ情報 英文 106 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.30円で換算しております。
骨髄線維症治療薬の世界市場:2018年~2022年 Global Myelofibrosis Therapeutics Market 2018-2022
出版日: 2018年12月21日 ページ情報: 英文 106 Pages
概要

骨髄線維症は、まれな変異であるフィラデルフィア染色体陰性骨髄増殖性腫瘍(MPN)のひとつです。 FDAが承認した唯一の薬物療法は、JAKAVI / JAKAFI(Ruxolitinib)です。骨髄線維症患者の治療に使用される効き目のある経口JAK1 / JAK2阻害剤です。HSCT療法はまた、適合ドナーの利用不可能性に関して不都合を有します。輸血およびアンドロゲン療法を含む他の療法は、骨髄線維症の貧血性副作用を軽減するだけです。したがって、現在利用可能なすべての治療法の中で、疾患の根絶に完全に役立つ理想的な治療法とみなせるものがありません。 Technavioのアナリストは、世界の骨髄線維症治療薬市場は2022年までに7%以上のCAGRで成長すると予測しています。

当レポートでは、世界の骨髄線維症治療薬市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 レポートの範囲

第3章 調査方法

第4章 市場状況

  • 市場エコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第5章 パイプライン分析

  • パイプライン分析

第6章 市場規模

市場の定義

  • 市場規模(2017年)
  • 市場規模および予測(2017年~2022年)

第7章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第8章 市場セグメンテーション:処置のタイプ別

  • セグメンテーション:治療の種類別
  • 治療の種類別比較:市場規模および予測(2017年~2022年)
  • 薬物療法
  • 輸血
  • HSCT
  • アンドロゲン療法
  • 市場機会:治療の種類別

第9章 顧客情勢

第10章 地域情勢

  • 地域別セグメンテーション
  • 地域比較:市場規模および予測(2017年~2022年)
  • 南北アメリカ
  • 欧州・中東・アフリカ地域
  • アジア太平洋地域
  • 市場機会

第11章 意思決定の枠組み

第12章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第13章 市場動向

  • HSCTは骨髄線維症に対する唯一の治療法の選択肢
  • ヒドロキシウレア、免疫調節剤、ステロイドなどの高用量適応外処方

第14章 ベンダー情勢

  • 概要
  • 創造的破壊の状況

第15章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Bristol-Myers Squibb
  • CELGENE
  • Incyte
  • Novartis

第16章 付録

  • 略語のリスト
図表
  • Exhibit 01: Global oncology therapeutics market
  • Exhibit 02: Global oncology therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Pipeline molecules for myelofibrosis 2017-2018
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2017
  • Exhibit 08: Validation techniques employed for market sizing 2017
  • Exhibit 09: Global - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 10: Global - Year-over-year growth 2018-2022 (%)
  • Exhibit 11: Five forces analysis 2017
  • Exhibit 12: Five forces analysis 2022
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2017
  • Exhibit 19: Type of treatment - Market share 2017-2022 (%)
  • Exhibit 20: Comparison by type of treatment
  • Exhibit 21: Drug therapy - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 22: JAKAVI/JAKAFI sales from 2015-2017
  • Exhibit 23: Drug therapy - Year-over-year growth 2018-2022 (%)
  • Exhibit 24: *Blood transfusion - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 25: Blood transfusion - Year-over-year growth 2018-2022 (%)
  • Exhibit 26: HSCT - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 27: HSCT - Year-over-year growth 2018-2022 (%)
  • Exhibit 28: Androgen therapy - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 29: Androgen Therapy - Year-over-year growth 2018-2022 (%)
  • Exhibit 30: Market opportunity by type of treatment
  • Exhibit 31: Customer landscape
  • Exhibit 32: Global - Market share by geography 2017-2022 (%)
  • Exhibit 33: Regional comparison
  • Exhibit 34: Americas - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 35: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 36: Top 3 countries in Americas
  • Exhibit 37: EMEA - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 38: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 39: Top 3 countries in EMEA
  • Exhibit 40: APAC - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 41: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 42: Top 3 countries in APAC
  • Exhibit 43: Market opportunity
  • Exhibit 44: Vendor landscape
  • Exhibit 45: Landscape disruption
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: Bristol-Myers Squibb - Overview
  • Exhibit 49: Bristol-Myers Squibb - Business segments
  • Exhibit 50: Bristol-Myers Squibb - Organizational developments
  • Exhibit 51: Bristol-Myers Squibb - Geographic focus
  • Exhibit 52: Bristol-Myers Squibb - Key offerings
  • Exhibit 53: Bristol-Myers Squibb - Key customers
  • Exhibit 54: CELGENE - Overview
  • Exhibit 55: CELGENE - Business segments
  • Exhibit 56: CELGENE - Organizational developments
  • Exhibit 57: CELGENE - Geographic focus
  • Exhibit 58: CELGENE - Key offerings
  • Exhibit 59: CELGENE - Key customers
  • Exhibit 60: Incyte - Overview
  • Exhibit 61: Incyte - Business segments
  • Exhibit 62: Incyte - Organizational developments
  • Exhibit 63: Incyte - Geographic focus
  • Exhibit 64: Incyte - Key offerings
  • Exhibit 65: Incyte - Key customers
  • Exhibit 66: Novartis - Overview
  • Exhibit 67: Novartis - Business segments
  • Exhibit 68: Novartis - Organizational developments
  • Exhibit 69: Novartis - Geographic focus
  • Exhibit 70: Novartis - Segment focus
  • Exhibit 71: Novartis - Key offerings
  • Exhibit 72: Novartis - Key customers
目次
Product Code: IRTNTR23859

About this market

Myelofibrosis is as Philadelphia chromosome- negative myeloproliferative neoplasm (MPN), a rare mutation. The only FDA approved drug therapy is JAKAVI/JAKAFI (Ruxolitinib). It is a potent oral JAK1/ JAK2 inhibitor used for treating the patients with myelofibrosis. HSCT therapy is also having disadvantages regarding the unavailability of matching donors. Other therapies, including the transfusion and androgen therapy, merely reduce the anemic side effects of myelofibrosis. Thus, among all treatments available at present, none can be considered as an ideal one that can completely help in eradicating the disease. Technavio's analysts have predicted that the myelofibrosis therapeutics market will register a CAGR of more than 7% by 2022.

Market Overview

Increasing number of companies entering the myelofibrosis segment

Before the launch of JAKAVI/JAKAFI, there were very few companies investing in the R&D of myelofibrosis therapies.

Limited market size as myelofibrosis is a rare disorder

The number of available therapies including the orphan drugs for this disorder is very limited. The treatment options employed by physicians are mostly the off- label drugs that are meant for the treatment of some other condition or the blood transfusion or stem cell transplantation.

For the detailed list of factors that will drive and challenge the growth of the myelofibrosis therapeutics market during the 2018-2022, view our report.

Competitive Landscape

The global myelofibrosis therapeutics market is extremely concentrated. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

  • Pipeline analysis

PART 06: MARKET SIZING

Market definition

  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: MARKET SEGMENTATION BY TYPE OF TREATMENT

  • Segmentation by type of treatment
  • Comparison by type of treatment
  • Drug therapy - Market size and forecast 2017-2022
  • Blood transfusion - Market size and forecast 2017-2022
  • HSCT - Market size and forecast 2017-2022
  • Androgen Therapy - Market size and forecast 2017-2022
  • Market opportunity by type of treatment

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • HSCT is the only curative option for myelofibrosis
  • High off-label prescription including hydroxyurea, Immunomodulators, and steroids

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb
  • CELGENE
  • Incyte
  • Novartis

PART 16: APPENDIX

  • List of abbreviations